Lidwien P. Smabers
YOU?
Author Swipe
View article: Figure 3 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Figure 3 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer Open
Genomic landscape of 36 tumors and/or PDOs derived from patients with mCRC. Top, microsatellite stability, tumor mutational load, tumor mutational burden, and whether the sequencing was performed on the PDOs or the tumor of origin; bottom,…
View article: Supplementary Data 1 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Supplementary Data 1 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer Open
Tables S1-S6 and Figures S1–S8
View article: Impact of treatment history on drug resistance of metastatic colorectal cancer organoids
Impact of treatment history on drug resistance of metastatic colorectal cancer organoids Open
The treatment of metastatic colorectal cancer (mCRC) is impeded by drug resistance. We investigated how prior chemotherapy affects tumor genotype, phenotype, and resistance mechanisms by comparing 35 patient-derived metastatic organoids (P…
View article: Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer Open
Purpose: Accurately predicting treatment response in metastatic colorectal cancer (mCRC) is critical to avoid unnecessary toxicity and improve patient outcomes. Patient-derived organoids (PDO) are promising models, but larger prospective s…
View article: Efficacy and safety in early-phase clinical trials for refractory colorectal cancer: A meta-analysis
Efficacy and safety in early-phase clinical trials for refractory colorectal cancer: A meta-analysis Open
Treatment efficacy in phase 1/2 trials is modest but improved from 2010 to 2021. This improvement is accompanied by a shift towards testing in a younger, fitter, and more strictly molecularly preselected population, as well as an increased…
View article: Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response
Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response Open
View article: External Validation of the Colon Life Nomogram for Predicting 12-Week Mortality in Dutch Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil in Daily Practice
External Validation of the Colon Life Nomogram for Predicting 12-Week Mortality in Dutch Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil in Daily Practice Open
Background: Predicting prognosis in refractory metastatic colorectal cancer (mCRC) patients is needed to guide decision making. The Colon Life nomogram was developed to predict 12-week mortality in refractory mCRC patients. The aim of this…